Zheng Quan Zhi Xing·2025-09-07 08:17Group 1 - The core viewpoint of the article is the verification opinion of CITIC Securities regarding the repurchase of convertible bonds issued by Shanghai Kehua Bio-engineering Co., Ltd. [1][7] - The issuance of Kehua convertible bonds was approved by the China Securities Regulatory Commission, with a total amount of 738 million yuan, and began trading on August 20, 2020 [1][2] - The conversion period for the bonds started on February 3, 2021, and will last until the maturity date on July 27, 2026 [2] Group 2 - The conditional repurchase clause allows bondholders to sell their bonds back to the company if the stock price falls below 70% of the conversion price for 30 consecutive trading days during the last two interest years [2][3] - The conversion price is set at 20.64 yuan per share, and the repurchase price will be the face value plus accrued interest [3][4] - The accrued interest for the sixth interest year is calculated to be 0.241 yuan per bond, resulting in a total repurchase price of 100.241 yuan per bond [5] Group 3 - The repurchase rights are not mandatory, allowing bondholders to choose whether to exercise their right to sell back the bonds [5][6] - The announcement period for the repurchase will begin the trading day after the conditions are met, with daily reminders until the end of the repurchase period [6] - The repurchase period for bondholders to submit their requests is from September 10 to September 16, 2025 [6] Group 4 - The company will continue trading the convertible bonds during the repurchase period but will suspend conversion rights [6] - CITIC Securities has confirmed that the repurchase matters comply with relevant regulations and the terms outlined in the offering prospectus [7]